drugset
drugset / Trial / NCT05867303

A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

NCT05867303 ↗

Phase 1 Active not recruiting 48 enrolled RemeGen Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Safety study of RC198 in Subjects with Solid Tumors.

Timeline

Start
2023-06-05
Primary completion
2024-09-30
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject RC198 Unknown — Subcutaneous

Indications

colorectal carcinoma head and neck squamous cell carcinoma melanoma non-small cell lung carcinoma renal cell carcinoma urothelial carcinoma